The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) published in NEJM in November 2023 redefined the therapeutic potential of GLP-1 receptor agonists. Prior cardiovascular outcomes trials (LEADER with liraglutide, SUSTAIN-6 with semaglutide) showed CV benefit primarily in patients with type 2 diabetes — and the benefit was long attributed to improved glycemic control. SELECT upended this by enrolling non-diabetic patients exclusively, proving the cardiovascular benefit of GLP-1 treatment operates independently of diabetes or glucose lowering.
The FDA subsequently approved Wegovy (semaglutide 2.4mg) in March 2024 with an expanded cardiovascular indication — the first obesity medication approved specifically to reduce the risk of cardiovascular events. This transformed semaglutide from a weight loss drug to a cardiovascular drug prescribed partly in a population that previously had no pharmacological cardiovascular intervention beyond statins and antihypertensives.
| Trial | Drug | Population | Primary Endpoint | Result |
|---|---|---|---|---|
| LEADER (2016) | Liraglutide 1.8mg QD | T2DM with high CV risk, N=9,340 | 3-point MACE | HR 0.87, 13% reduction (p=0.01) |
| SUSTAIN-6 (2016) | Semaglutide SC 0.5 or 1mg | T2DM with CV disease, N=3,297 | 3-point MACE | HR 0.74, 26% reduction (p<0.001) |
| PIONEER 6 (2019) | Oral semaglutide 14mg | T2DM with CV risk, N=3,183 | 3-point MACE | HR 0.79, 21% reduction (non-inferiority; not superiority powered) |
| SELECT (2023) | Semaglutide SC 2.4mg QW | No T2DM, BMI≥27 + established CVD, N=17,604 | 3-point MACE | HR 0.80, 20% reduction (p<0.001) ← landmark |
| FLOW (2024) | Semaglutide SC 1mg | T2DM with chronic kidney disease, N=3,533 | Kidney failure/CV death | HR 0.76, 24% reduction — trial stopped early for efficacy |
| SURPASS-CVOT (expected 2025–2026) | Tirzepatide (GIP+GLP-1) | T2DM with established CVD | 3-point MACE | Pending — expected to show at least semaglutide-equivalent or superior CV benefit given greater weight loss |
The honest answer: probably both, and the relative contributions are genuinely uncertain. The argument for direct GLP-1 mechanisms is supported by the early curve separation in SELECT (cardiovascular benefits appear before meaningful weight loss), GLP-1 receptor expression in cardiomyocytes and coronary endothelium (suggesting direct cardioprotective signaling), anti-inflammatory effects on macrophages in atherosclerotic plaques (reduced MCP-1, IL-6, TNF-α), improved endothelial function independent of weight, and blood pressure reduction (–3–5 mmHg) that exceeds what's expected from weight loss alone.
The argument for weight-mediated benefit: the magnitude of CV risk reduction in SELECT correlates with weight lost over the trial; landmark analyses showing early benefit may simply reflect very rapid metabolic improvement from initial GLP-1 effects on insulin resistance, inflammation, and visceral fat mobilization — all of which begin within weeks of treatment. Epidemiologically, weight loss of 5–10% consistently reduces CV risk markers. At –15% body weight over 3 years in SELECT, meaningful CV risk reduction is expected from weight loss alone.
The practical implication is the same either way: semaglutide reduces cardiovascular events by 20% in high-risk obese adults, and this benefit is now FDA-label-indicated regardless of the underlying mechanism.
GLP-1 receptors (GLP-1R) are expressed in multiple cardiovascular tissues beyond the pancreas. In arterial endothelium, GLP-1R activation increases nitric oxide (NO) production, reduces oxidative stress via NADPH oxidase suppression, and decreases ICAM-1/VCAM-1 expression — reducing monocyte adhesion, the first step in atherosclerotic plaque formation. In macrophages within plaques, GLP-1R signaling polarizes toward anti-inflammatory M2 phenotype and reduces foam cell formation by suppressing cholesterol uptake. In cardiomyocytes, GLP-1R activation improves mitochondrial function and reduces apoptosis during ischemia-reperfusion injury.
C-reactive protein (CRP) — a key marker of systemic inflammation and independent predictor of CV events — decreases 40% with semaglutide treatment in SELECT, with this reduction partially independent of weight lost. The CANTOS trial (canakinumab, an IL-1β antibody) showed that directly targeting inflammation (independent of lipid-lowering) reduces CV events — providing a mechanistic framework for understanding how anti-inflammatory GLP-1 effects might reduce cardiovascular risk beyond weight loss.
Who SELECT enrolled (and who the indication applies to): Adults aged ≥45 with BMI ≥27 (overweight or obese) AND established cardiovascular disease (prior MI, stroke, or peripheral arterial disease) WITHOUT type 2 diabetes. The SELECT indication does NOT apply to people without pre-existing cardiovascular disease — that cardiovascular prevention benefit in lower-risk populations is not yet demonstrated.
What the 20% MACE reduction means in absolute terms: In the placebo arm, 8% had a MACE event over 3.3 years; in the semaglutide arm, 6.5% had a MACE event. Absolute risk reduction: ~1.5 percentage points. Number needed to treat (NNT): approximately 67 patients treated for 3.3 years to prevent 1 MACE event. For context: statins in secondary prevention typically have NNT of 50–100 for similar timeframes. This is a clinically meaningful effect.
Beyond SELECT — other emerging indications: FLOW trial (2024) showed 24% reduction in kidney disease progression/CV death in diabetic CKD; semaglutide is now FDA-approved for nephroprotection. Heart failure with preserved ejection fraction (HFpEF): STEP-HFpEF trial showed semaglutide improved symptoms and functional capacity in HFpEF by 13 points on KCCQ vs 2.3 placebo (p<0.001), FDA approved 2024. Sleep apnea: SURMOUNT-OSA trial with tirzepatide showed 63% reduction in apnea events — likely the largest effect size ever shown for any obesity intervention on OSA.
Insurance coverage reality (2026): The cardiovascular SELECT indication substantially changed payer coverage. CMS covers Wegovy for Medicare Part D beneficiaries with established CVD — the first obesity drug covered by Medicare. Many commercial insurers now cover semaglutide with cardiovascular indication for qualifying patients. The SELECT data effectively repositioned Wegovy from "lifestyle drug" to "cardiovascular medicine."